Technoderma Medicines' TDM-180935, a topical JAK-1/TYK-2 inhibitor, demonstrated efficacy in a Phase 2a trial for atopic dermatitis, with the 2% formulation showing the most promise.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.